ABSTRACT
Electrophysiological technique is an efficient tool for investigating the synaptic regulatory effects mediated by the endocannabinoid system. Stimulation of presynaptic type 1 cannabinoid receptor (CB1) is the principal mode by which endocannabinoids suppress transmitter release in the central nervous system, but a non-retrograde manner of functioning and other receptors have also been described. Endocannabinoids are key modulators of both short- and long-term plasticity. Here, we discuss ex vivo electrophysiological approaches to examine synaptic signaling induced by cannabinoid and endocannabinoid molecules in the mammalian brain.
Subject(s)
Cannabinoids , Endocannabinoids , Animals , Cannabinoid Receptor Modulators/pharmacology , Cannabinoid Receptor Modulators/physiology , Mammals , Receptors, Cannabinoid , Signal Transduction/physiology , Synaptic TransmissionABSTRACT
The endocannabinoid system is widely expressed both in the brain and in the periphery. This system regulates a plethora of physiological functions and is composed of cannabinoid receptors, their endogenous ligands, and the enzymes involved in their metabolic processes. In the last few years, the development of new imaging and molecular tools has demonstrated that these receptors are distributed in many cell types (e.g., neuronal or glial cells) and intracellular compartments (e.g., mitochondria). Interestingly, cellular or molecular effects are differentially mediated by cannabinoid receptors according to their specific localization in different cell-types or in different subcellular locations. Moreover, the endocannabinoid system is also expressed throughout the body where it can serve to modulate the connection between the brain and the periphery. Finally, better understanding of the cannabinoid receptors structure and pharmacology has led researchers to propose interesting and new allosteric modulators of synaptic communication. The latest advances and innovative research in the cannabinoid field will provide new insights and better approaches to improve its interesting potential therapeutic profile. This special issue intends to bring together a series of empirical papers, targeted reviews and opinions from leaders in the field that will highlight the new advances in cannabinoid research.
Subject(s)
Cannabinoids , Endocannabinoids , Receptors, Cannabinoid , Brain/metabolism , Cannabinoid Receptor Modulators/pharmacology , Cannabinoid Receptor Modulators/physiology , Cannabinoids/metabolism , Cannabinoids/pharmacology , Endocannabinoids/metabolism , Receptors, Cannabinoid/metabolism , Signal TransductionABSTRACT
The endocannabinoid system participates in the regulation of CNS homeostasis and functions, including neurotransmission, cell signaling, inflammation and oxidative stress, as well as neuronal and glial cell proliferation, differentiation, migration and survival. Endocannabinoids are produced by multiple cell types within the CNS and their main receptors, CB1 and CB2, are expressed in both neurons and glia. Signaling through these receptors is implicated in the modulation of neuronal and glial alterations in neuroinflammatory, neurodegenerative and psychiatric conditions, including Alzheimer's, Parkinson's and Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, stroke, epilepsy, anxiety and depression. The therapeutic potential of endocannabinoid receptors in neurological disease has been hindered by unwelcome side effects of current drugs used to target them; however, due to their extensive expression within the CNS and their involvement in physiological and pathological process in nervous tissue, they are attractive targets for drug development. The present review highlights the potential applications of the endocannabinoid system for the prevention and treatment of neurologic and psychiatric disorders.
Subject(s)
Mental Disorders/drug therapy , Mental Disorders/prevention & control , Nervous System Diseases/drug therapy , Nervous System Diseases/prevention & control , Receptors, Cannabinoid/drug effects , Receptors, Cannabinoid/physiology , Animals , Brain/drug effects , Brain/metabolism , Brain/physiopathology , Cannabinoid Receptor Agonists/pharmacology , Cannabinoid Receptor Antagonists/pharmacology , Cannabinoid Receptor Modulators/physiology , Endocannabinoids , Humans , Inflammation/metabolism , Mental Disorders/physiopathology , Nervous System Diseases/physiopathology , Neuronal Plasticity/physiology , Neurons/metabolismABSTRACT
The endocannabinoid system is an endogenous pathway comprised of the cannabinoid receptors 1 and 2 (CB1 and CB2), their endogenous ligands known as endocannabinoids, and the enzymes responsible for their synthesis and degradation. The endocannabinoidome extends this system to include other receptors such as TRPV1, PPARα, GPR55 and 5-HT1A. An extensive amount of research is now linking the endocannabinoidome to intestinal health through fascinating mechanisms that include endocannabinoid receptor expression in the gut and interplay with the intestinal microbiota. A dysregulated endocannabinoid system may lead to inflammatory bowel disease and colon cancer.
Subject(s)
Cannabinoid Receptor Modulators/pharmacology , Endocannabinoids , Gastrointestinal Microbiome , Gastrointestinal Tract/drug effects , Cannabinoid Receptor Modulators/physiology , Gastrointestinal Tract/physiology , Gastrointestinal Tract/physiopathology , Humans , Receptor, Cannabinoid, CB1/physiology , Receptor, Cannabinoid, CB2/physiologyABSTRACT
The skin serves as the foremost barrier between the internal body and the external world, providing crucial protection against pathogens and chemical, mechanical, and ultraviolet damages. The skin is a central player in the intricate network of immune, neurologic, and endocrine systems. The endocannabinoid system (ECS) includes an extensive network of bioactive lipid mediators and their receptors, functions to modulate appetite, pain, mood, and memory, and has recently been implicated in skin homeostasis. Disruption of ECS homeostasis is implicated in the pathogenesis of several prevalent skin conditions. In this review, we highlight the role of endocannabinoids in maintaining skin health and homeostasis and discuss evidence on the role of ECS in several eczematous dermatoses including atopic dermatitis, asteatotic eczema, irritant contact dermatitis, allergic contact dermatitis, and chronic pruritus. The compilation of evidence may spark directions for future investigations on how the ECS may be a therapeutic target for dermatologic conditions.
Subject(s)
Cannabinoid Receptor Modulators/physiology , Endocannabinoids/physiology , Skin Diseases, Eczematous/physiopathology , Humans , Skin Physiological PhenomenaABSTRACT
Endocannabinoids exert their effect on the regulation of energy homeostasis via activation of specific receptors. They control food intake, secretion of insulin, lipids and glucose metabolism, lipid storage. Long chain fatty acids are the main myocardial energy substrate. However, the heart exerts enormous metabolic flexibility emphasized by its ability to utilzation not only fatty acids, but also glucose, lactate and ketone bodies. Endocannabinoids can directly act on the cardiomyocytes through the CB1 and CB2 receptors present in cardiomyocytes. It appears that direct activation of CB1 receptors promotes increased lipogenesis, pericardial steatosis and bioelectrical dysfunction of the heart. In contrast, stimulation of CB2 receptors exhibits cardioprotective properties, helping to maintain appropriate amount of ATP in cardiomyocytes. Furthermore, the effects of endocannabinoids at both the central nervous system and peripheral tissues, such as liver, pancreas, or adipose tissue, resulting indirectly in plasma availability of energy substrates and affects myocardial metabolism. To date, there is little evidence that describes effects of activation of the endocannabinoid system in the cardiovascular system under physiological conditions. In the present paper the impact of metabolic diseases, i. e. obesity and diabetes, as well as the cardiovascular diseases - hypertension, myocardial ischemia and myocardial infarction on the deregulation of the endocannabinoid system and its effect on the metabolism are described.
Subject(s)
Cardiovascular Diseases/metabolism , Diabetes Mellitus/metabolism , Endocannabinoids/metabolism , Energy Metabolism , Myocardium/metabolism , Obesity/metabolism , Adipose Tissue/metabolism , Adipose Tissue/physiopathology , Animals , Cannabinoid Receptor Modulators/metabolism , Cannabinoid Receptor Modulators/physiology , Cardiovascular Diseases/physiopathology , Diabetes Mellitus/physiopathology , Eating , Endocannabinoids/physiology , Heart/physiopathology , Humans , Liver/metabolism , Liver/physiopathology , Obesity/physiopathology , Pancreas/metabolism , Pancreas/physiopathologyABSTRACT
Cannabis is one of the most prevalent drugs used in industrialized countries. The main effects of Cannabis are mediated by two major exogenous cannabinoids: ∆9-tetrahydroxycannabinol and cannabidiol. They act on specific endocannabinoid receptors, especially types 1 and 2. Mammals are endowed with a functional cannabinoid system including cannabinoid receptors, ligands, and enzymes. This endocannabinoid signaling pathway is involved in both physiological and pathophysiological conditions with a main role in the biology of the central nervous system. As the retina is a part of the central nervous system due to its embryonic origin, we aim at providing the relevance of studying the endocannabinoid system in the retina. Here, we review the distribution of the cannabinoid receptors, ligands, and enzymes in the retina and focus on the role of the cannabinoid system in retinal neurobiology. This review describes the presence of the cannabinoid system in critical stages of retinal processing and its broad involvement in retinal neurotransmission, neuroplasticity, and neuroprotection. Accordingly, we support the use of synthetic cannabinoids as new neuroprotective drugs to prevent and treat retinal diseases. Finally, we argue for the relevance of functional retinal measures in cannabis users to evaluate the impact of cannabis use on human retinal processing.
Subject(s)
Cannabinoid Receptor Modulators/physiology , Endocannabinoids/physiology , Neuronal Plasticity/physiology , Retina/physiology , Animals , Cannabinoid Receptor Modulators/therapeutic use , Endocannabinoids/therapeutic use , Humans , Neuroprotective Agents/therapeutic use , Receptors, Cannabinoid/physiology , Retinal Degeneration/drug therapy , Retinal Degeneration/physiopathology , Signal Transduction/physiologyABSTRACT
Cannabinoids (Δ9-tetrahydrocannabinol) are the active ingredient of marijuana (cannabis) which is the most commonly abused illicit drug in the USA. In addition to being known and used as recreational drugs, cannabinoids are produced endogenously by neurons in the brain (endocannabinoids) and serve as important signaling molecules in the nervous system and the rest of the body. Cannabinoids have been implicated in bodily processes both in health and disease. Recent pharmacological and physiological experiments have described novel aspects of classic brain signaling mechanisms or revealed unknown mechanisms of cellular communication involving the endocannabinoid system. While several forms of signaling have been described for endocannabinoids, the most distinguishing feature of endocannabinoids is their ability to act as retrograde messengers in neural circuits. Neurons in the main olfactory bulb express high levels of cannabinoid receptors. Here, we describe the cellular mechanisms and function of this novel brain signaling system in regulating neural activity at synapses in olfactory circuits. Results from basic research have the potential to provide the groundwork for translating the neurobiology of drug abuse to the realm of the pharmacotherapeutic treatment of addiction, specifically marijuana substance use disorder.
Subject(s)
Brain/drug effects , Cannabinoid Receptor Modulators/physiology , Endocannabinoids/physiology , Marijuana Abuse/physiopathology , Neurons/drug effects , Receptors, Cannabinoid/drug effects , Signal Transduction/drug effects , Cannabis/chemistry , Humans , Smell/drug effects , United StatesABSTRACT
The internal state of the organism is an important modulator of perception and behavior. The link between hunger, olfaction and feeding behavior is one of the clearest examples of these connections. At the neurobiological level, olfactory circuits are the targets of several signals (i.e. hormones and nutrients) involved in energy balance. This indicates that olfactory areas are potential sensors of the internal state of the organism. Thus, the aim of this manuscript is to review the literature showing the interplay between metabolic signals in olfactory circuits and its impact on food intake.
Subject(s)
Eating , Endocannabinoids/physiology , Energy Metabolism , Feeding Behavior , Olfactory Perception , Animals , Cannabinoid Receptor Modulators/metabolism , Cannabinoid Receptor Modulators/physiology , Endocannabinoids/metabolism , Energy Intake , Glucose/metabolism , Lipid Metabolism , Models, Biological , SmellABSTRACT
The endocannabinoid system (SEC) is an important modulator of several metabolic functions. This system is composed by cannabinoid receptors type 1 and 2 (RCB1 and RCB2), their endogenous ligands, known as endocannabinoids, and the enzymes involved in their synthesis and degradation. A deregulated SEC originates metabolic alterations in several tissues, resulting in the typical manifestations of the metabolic syndrome. Liver steatosis of different origins constitutes a physiopathological condition where an altered hepatic SEC is observed. In this condition, there is an increased expression of RCB1 and/or higher endocannabinoid levels in different hepatic cells, which may exert an autocrine/paracrine hyperstimulation of RCB1/RCB2. Activation of RCB1 stimulate the expression of several hepatocyte lipogenic factors, thus leading to increased de novo fatty acids synthesis and consequently to an abnormal accumulation of triglycerides. The effect of RCB2 activity on hepatic function is still controversial because, on one side its stimulation has an interesting protective effect on alcoholic liver disease while, on the other, it may enhance the development of hepatic steatosis in experimental models of diet-induced obesity. In this review we discuss the proposed mechanisms by which SEC is involved in the etiology of hepatic steatosis, as well as the therapeutic possibilities involving peripheral RCB1/RCB2 antagonism/agonism, for the treatment of this condition.
Subject(s)
Cannabinoid Receptor Modulators/physiology , Endocannabinoids/physiology , Fatty Liver/etiology , Receptor, Cannabinoid, CB1/physiology , Fatty Liver/physiopathology , Humans , Receptor, Cannabinoid, CB2/physiologyABSTRACT
The endocannabinoid system (SEC) is an important modulator of several metabolic functions. This system is composed by cannabinoid receptors type 1 and 2 (RCB1 and RCB2), their endogenous ligands, known as endocannabinoids, and the enzymes involved in their synthesis and degradation. A deregulated SEC originates metabolic alterations in several tissues, resulting in the typical manifestations of the metabolic syndrome. Liver steatosis of different origins constitutes a physiopathological condition where an altered hepatic SEC is observed. In this condition, there is an increased expression of RCB1 and/or higher endocannabinoid levels in different hepatic cells, which may exert an autocrine/paracrine hyperstimulation of RCB1/RCB2. Activation of RCB1 stimulate the expression of several hepatocyte lipogenic factors, thus leading to increased de novo fatty acids synthesis and consequently to an abnormal accumulation of triglycerides. The effect of RCB2 activity on hepatic function is still controversial because, on one side its stimulation has an interesting protective effect on alcoholic liver disease while, on the other, it may enhance the development of hepatic steatosis in experimental models of diet-induced obesity. In this review we discuss the proposed mechanisms by which SEC is involved in the etiology of hepatic steatosis, as well as the therapeutic possibilities involving peripheral RCB1/RCB2 antagonism/agonism, for the treatment of this condition.
Subject(s)
Humans , Cannabinoid Receptor Modulators/physiology , Endocannabinoids/physiology , Fatty Liver/etiology , Receptor, Cannabinoid, CB1/physiology , Fatty Liver/physiopathology , /physiologyABSTRACT
In overview one can find up-today data on endogenous cannabinoids (EC), their role in brain functioning. Interest in EC in recent years has significantly increased. Despite the fact that existence of EC-system among mammals was identified in nineties of the twenties century, deciphering the mechanisms of its functioning both in healthy brain as well in various pathologies, is far from final stage. The main function of EC in brain is implementation of the retrograde synaptic function of communication and neuromodulation. In overview one can see data on localization and functions of cannabinoids receptors and its endogenous ligands in CMS, as well as on EC-system participation in epileptiform activity modulation. Special focus on the analysis of works, where the projection revealed the role of EC in experimental modeling of the temporal epilepsy with animals, as well as for diseases in humans epilepsy. Set out the estimated survival mechanisms of cells and their repair provided by cannabinoid system in the generation of seizure activity; also provides information about the neurotoxic effects of EC. Possible reasons of contradictions are being discussed, that exist in the literature regarding the functions of EC in the brain.
Subject(s)
Brain , Endocannabinoids/metabolism , Receptor, Cannabinoid, CB1/metabolism , Receptor, Cannabinoid, CB2/metabolism , Animals , Brain/metabolism , Brain/physiology , Cannabinoid Receptor Modulators/metabolism , Cannabinoid Receptor Modulators/physiology , Endocannabinoids/physiology , Humans , Nervous System Physiological Phenomena , Receptor, Cannabinoid, CB1/physiology , Receptor, Cannabinoid, CB2/physiology , Seizures/metabolism , Seizures/physiopathology , Signal TransductionABSTRACT
The 'thrifty gene hypothesis' posits that evolution preferentially selects physiological mechanisms that optimize energy storage to increase survival under alternating conditions of abundance and scarcity of food. Recent experiments suggest that endocannabinoids - a class of lipid-derived mediators that activate cannabinoid receptors in many cells of the body - are key agents of energy conservation. The new evidence indicates that these compounds increase energy intake and decrease energy expenditure by controlling the activity of peripheral and central neural pathways involved in the sensing and hedonic processing of sweet and fatty foods, as well as in the storage of their energy content for future use.
Subject(s)
Brain/physiology , Cannabinoid Receptor Modulators/physiology , Endocannabinoids , Energy Intake/physiology , Energy Metabolism/physiology , Lipids , Animals , HumansABSTRACT
Astrocytes are integral functional components of synapses, regulating transmission and plasticity. They have also been implicated in the pathogenesis of epilepsy, although their precise roles have not been comprehensively characterized. Astrocytes integrate activity from neighboring synapses by responding to neuronally released neurotransmitters such as glutamate and ATP. Strong activation of astrocytes mediated by these neurotransmitters can promote seizure-like activity by initiating a positive feedback loop that induces excessive neuronal discharge. Recent work has demonstrated that astrocytes express cannabinoid 1 (CB1) receptors, which are sensitive to endocannabinoids released by nearby pyramidal cells. In this study, we tested whether this mechanism also contributes to epileptiform activity. In a model of 4-aminopyridine induced epileptic-like activity in hippocampal slice cultures, we show that pharmacological blockade of astrocyte CB1 receptors did not modify the initiation, but significantly reduced the maintenance of epileptiform discharge. When communication in astrocytic networks was disrupted by chelating astrocytic calcium, this CB1 receptor-mediated modulation of epileptiform activity was no longer observed. Thus, endocannabinoid signaling from neurons to astrocytes represents an additional significant factor in the maintenance of epileptiform activity in the hippocampus.
Subject(s)
Astrocytes/physiology , Cell Communication/physiology , Epilepsy/physiopathology , Hippocampus/physiology , Neurons/physiology , Receptor, Cannabinoid, CB1/physiology , 4-Aminopyridine/pharmacology , Animals , Cannabinoid Receptor Modulators/physiology , Epilepsy/chemically induced , Patch-Clamp Techniques , Rats , Rats, Wistar , Synaptic Transmission/physiologyABSTRACT
The treatment of cannabis dependence can be viewed as a cup half empty or half full. On the one hand, few people who might benefit from treatment actually receive it. Among those who undergo treatment in randomized trials, long-term abstinence is achieved by fewer than 20%. Moderate use goals have been associated with decreases in consequences, but the differential impact of such goals on the long-term course of cannabis dependence is unknown. Optimal duration of treatment is unclear, and certain populations, particularly patients with co-occurring disorders, have not been studied adequately. Twelve-step programs are low cost, effective for other substance use disorders, and readily available in most regions of the world. However, their role and efficacy in cannabis dependence has not been examined. Finally, effective pharmacologic treatments are under development, but none have yet been firmly established. On the other hand, psychotherapeutic strategies used to treat other substance use disorders can be effective for cannabis dependence. A recent meta-analysis of psychosocial interventions for illicit substance use disorders found that treatments for cannabis dependence had comparatively larger effect sizes than treatments for other substance use disorders. Combination therapies have proven most effective, particularly those that begin with a motivational intervention, utilize incentives to enhance the commitment to change, and teach behavioral and cognitive copings skills to prevent relapse. Among adolescents, family engagement and collaboration with community stakeholders adds substantial value. Although only 9% of cannabis users develop cannabis dependence, the volume of people who smoke cannabis ensures that the total number of people in need of help is larger than the capacity of substance abuse specialty services. Thus, although efforts to refine and improve the efficacy of treatment interventions continue, innovations that increase the availability and accessibility of treatment are also needed. Computer- and phone-based interventions, social media, and brief interventions that can be implemented in primary care settings are areas that may hold promise for reaching at-risk populations. Adolescents and persons with co-occurring mental illness are at particularly high risk of cannabis dependence, and may suffer disproportionately from cannabis's adverse effects. As in the treatment of other substance use disorders, there is a need for a continuing care model with long-term follow-up that extends past the periods typically evaluated in treatment studies. Additionally, there is a need for further investigation of genetic underpinnings and endophenotypes underlying cannabis dependence to identify neurobiological mechanisms for targeted intervention. One benefit of the societal focus on cannabis has been a prominent increase in research covering everything from the basic science to public health impact of cannabis. Over the next decade, physicians who provide treatment for individuals with cannabis dependence are likely to see their armamentarium of effective interventions expand, to the ultimate betterment of patients, their families, and society at large.
Subject(s)
Cannabinoid Receptor Modulators/physiology , Cannabinoids/adverse effects , Marijuana Abuse/therapy , Neurotransmitter Agents/therapeutic use , Psychotherapy/methods , Substance Withdrawal Syndrome/drug therapy , Animals , Cannabinoid Receptor Modulators/metabolism , Combined Modality Therapy , Comorbidity , Depressive Disorder/drug therapy , Depressive Disorder/epidemiology , Humans , Marijuana Abuse/epidemiology , Marijuana Abuse/psychology , Randomized Controlled Trials as Topic , Risk Factors , Substance Withdrawal Syndrome/epidemiologyABSTRACT
The anticonvulsant properties of marijuana have been known for centuries. The recently characterized endogenous cannabinoid system thus represents a promising target for novel anticonvulsant agents; however, administration of exogenous cannabinoids has shown mixed results in both human epilepsy and animal models. The ability of cannabinoids to attenuate release of both excitatory and inhibitory neurotransmitters may explain the variable effects of cannabinoids in different models of epilepsy, but this has not been well explored. Using acute mouse brain slices, we monitored field potentials in the CA1 region of the hippocampus to characterize systematically the effects of the cannabinoid agonist WIN55212-2 (WIN) on evoked basal and epileptiform activity. WIN, acting presynaptically, significantly reduced the amplitude and slope of basal field excitatory postsynaptic potentials as well as stimulus-evoked epileptiform responses induced by omission of magnesium from the extracellular solution. In contrast, the combination of omission of magnesium plus elevation of potassium induced an epileptiform response that was refractory to attenuation by WIN. The effect of WIN in this model was partially restored by blocking γ-aminobutyric acid type B (GABA(B) ), but not GABA(A) , receptors. Subtle differences in models of epileptiform activity can profoundly alter the efficacy of cannabinoids. Endogenous GABA(B) receptor activation played a role in the decreased cannabinoid sensitivity observed for epileptiform activity induced by omission of magnesium plus elevation of potassium. These results suggest that interplay between presynaptic G protein-coupled receptors with overlapping downstream targets may underlie the variable efficacy of cannabinoids in different models of epilepsy.
Subject(s)
Anticonvulsants/pharmacology , Benzoxazines/pharmacology , CA1 Region, Hippocampal/drug effects , Cannabinoids/pharmacology , Epilepsy/drug therapy , Morpholines/pharmacology , Naphthalenes/pharmacology , Receptors, GABA-B/physiology , Animals , CA1 Region, Hippocampal/physiopathology , Cannabinoid Receptor Modulators/physiology , Drug Resistance/physiology , Epilepsy/physiopathology , Humans , Mice , Mice, Inbred Strains , Organ Culture TechniquesABSTRACT
Hippocampal CA1 pyramidal neurons receive sensory inputs from the entorhinal cortex directly through the perforant path (PP) and indirectly through Schaffer collaterals (SC). Direct cortical inputs to CA1 pyramidal neurons through the PP provide instructive signals for hippocampal long-term synaptic plasticity. However, the molecules conveying synaptic signalling in this new form of heterosynaptic plasticity remain unclear. Endocannabinoids, important endogenous signalling mediators, modulate synaptic efficacy primarily through inhibition of GABAergic or glutamatergic synaptic transmission via presynaptically expressed CB1 receptors. Here, we report that pairing of direct and indirect cortical inputs to CA1 pyramidal neurons resulted in a long-lasting potentiation of synaptic responses at SC synapses, but not at the PP. The pairing-potentiated synaptic transmission at the SC was accompanied by a reduced ratio of paired-pulse facilitation (PPR). Enhanced synaptic response at the SC by pairing of PPSC stimuli is Ca(2+) dependent and requires the presence of functional GABAergic and glutamatergic synaptic transmissions and activation of group I metabotropic glutamate receptors. Pharmacological inhibition or genetic deletion of the CB1 receptor eliminated the pairing-induced long-term synaptic plasticity and decreased PPR at the SC. The potentiation induced by pairing of PPSC stimuli primarily is the glutamatergic synaptic transmission. While the pairing-induced long-lasting potentiation of synaptic response was blocked by inhibitors for diacylglycerol lipase (DGL), which biosynthesizes 2-AG, inhibition of monoacylglycerol lipase (MAGL), which metabolizes 2-AG, facilitated the potentiation at SC synapses by pairing of weak PPSC stimuli. Our results suggest that 2-AG functions as a signalling mediator tuning synaptic efficacy at the proximal synapses of hippocampal CA1 pyramidal neurons while direct and indirect cortical inputs to the same neurons are spatiotemporally primed.
Subject(s)
Arachidonic Acids/physiology , CA1 Region, Hippocampal/physiology , Cannabinoid Receptor Modulators/physiology , Endocannabinoids , Entorhinal Cortex/physiology , Glycerides/physiology , Pyramidal Cells/physiology , Synaptic Transmission/physiology , Animals , Calcium/physiology , Female , In Vitro Techniques , Long-Term Potentiation/physiology , Male , Mice , Mice, Knockout , Perforant Pathway/physiology , Rats , Rats, Sprague-Dawley , Receptor, Cannabinoid, CB1/physiology , Receptors, Metabotropic Glutamate/physiologyABSTRACT
Over the past fifty years a significant body of evidence has been compiled suggesting an interaction between the endocannabinoid (EC) system and alcohol dependence. However, much of this work has been conducted only in the past two decades following the elucidation of the molecular constituents of the EC system that began with the serendipitous discovery of the cannabinoid 1 receptor (CB1). Since then, novel pharmacological and genetic tools have enabled researchers to manipulate select components of the EC system, to determine their contribution to the motivation to consume ethanol. From these preclinical studies, it is evident that CB1 contributes the motivational and reinforcing properties of ethanol, and chronic consumption of ethanol alters EC transmitter levels and CB1 expression in brain nuclei associated with addiction pathways. These results are augmented by in vitro and ex vivo studies showing that acute and chronic treatment with ethanol produces physiologically relevant alterations in the function of the EC system. This report provides a current and comprehensive review of the literature regarding the interactions between ethanol and the EC system. We begin be reviewing the studies published prior to the discovery of the EC system that compared the behavioral and physiological effects of cannabinoids with ethanol in addition to cross-tolerance between these drugs. Next, a brief overview of the molecular constituents of the EC system is provided as context for the subsequent review of more recent studies examining the interaction of ethanol with the EC system. These results are compiled into a summary providing a scheme for the known changes to the components of the EC system in different stages of alcohol dependence. Finally, future directions for research are discussed.
Subject(s)
Alcohol-Related Disorders/physiopathology , Cannabinoid Receptor Modulators/physiology , Endocannabinoids , Ethanol/pharmacology , Receptors, Cannabinoid/drug effects , Alcoholism/genetics , Alcoholism/physiopathology , Animals , Cannabinoids/pharmacology , Comorbidity , Drug Tolerance , Ethanol/metabolism , Humans , Mice , Rats , Receptor, Cannabinoid, CB1/metabolism , Receptors, Cannabinoid/metabolism , Stress, Psychological/physiopathology , Substance Withdrawal Syndrome/drug therapyABSTRACT
INTRODUCTION: Dementia currently affects over 35 million people worldwide. The most common form of dementia is Alzheimer's disease (AD). Currently, treatments for AD do not stop or reverse the progression of the disease and they are accompanied by side effects. AREAS COVERED: The main features of AD pathology, treatment options currently available, the endocannabinoid system and its functionality in general and its role in AD pathology in detail will be outlined. A particular focus will be on the therapeutic potential of the phytocannabinoid cannabidiol. EXPERT OPINION: Based on the complex pathology of AD, a preventative, multimodal drug approach targeting a combination of pathological AD symptoms appears ideal. Importantly, cannabinoids show anti-inflammatory, neuroprotective and antioxidant properties and have immunosuppressive effects. Thus, the cannabinoid system should be a prime target for AD therapy. The cannabinoid receptor 2 appears to be a promising candidate but its role in AD has to be investigated cautiously. Furthermore, the phytocannabinoid cannabidiol is of particular interest as it lacks the psychoactive and cognition-impairing properties of other cannabinoids. In conclusion, future research should focus on the evaluation of the effects of manipulations to the endocannabinoid system in established animal models for AD, combined with early-phase studies in humans.
Subject(s)
Alzheimer Disease/drug therapy , Cannabinoid Receptor Modulators/physiology , Endocannabinoids , Alzheimer Disease/metabolism , Alzheimer Disease/physiopathology , Animals , Cannabidiol/pharmacology , Humans , Memory/physiologyABSTRACT
There is extensive evidence that glucocorticoid hormones impair the retrieval of memory of emotionally arousing experiences. Although it is known that glucocorticoid effects on memory retrieval impairment depend on rapid interactions with arousal-induced noradrenergic activity, the exact mechanism underlying this presumably nongenomically mediated glucocorticoid action remains to be elucidated. Here, we show that the hippocampal endocannabinoid system, a rapidly activated retrograde messenger system, is involved in mediating glucocorticoid effects on retrieval of contextual fear memory. Systemic administration of corticosterone (0.3-3 mg/kg) to male Sprague-Dawley rats 1 h before retention testing impaired the retrieval of contextual fear memory without impairing the retrieval of auditory fear memory or directly affecting the expression of freezing behavior. Importantly, a blockade of hippocampal CB1 receptors with AM251 prevented the impairing effect of corticosterone on retrieval of contextual fear memory, whereas the same impairing dose of corticosterone increased hippocampal levels of the endocannabinoid 2-arachidonoylglycerol. We also found that antagonism of hippocampal ß-adrenoceptor activity with local infusions of propranolol blocked the memory retrieval impairment induced by the CB receptor agonist WIN55,212-2. Thus, these findings strongly suggest that the endocannabinoid system plays an intermediary role in regulating rapid glucocorticoid effects on noradrenergic activity in impairing memory retrieval of emotionally arousing experiences.